What is the 13F Pro Quality Score for NRXS?

13F Pro ranks Neuraxis, INC (NRXS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NRXS's current score at https://13fpro.ai/company/NRXS (free sign-up required for the full ranking).

Where does 13F Pro source NRXS data?

All Neuraxis, INC fundamentals and ownership data come directly from SEC EDGAR. Neuraxis, INC files with the SEC under CIK 1933567. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NRXS in?

Neuraxis, INC (NRXS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NRXS research updated on 13F Pro?

NRXS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Neuraxis, INC(NRXS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1933567 NRXS stock profile & AI dashboard →

13F Pro Quality Score

32.1/100

Rank #2,435 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NRXS Scores 32/100

exact factor attribution · 2026-09-11

NRXS's composite is driven by revenue growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.5 pts

92th pct

Institutional flow

+0.7 pts

63th pct

Earnings growth

-1.1 pts

27th pct

Earnings quality

-1.5 pts

35th pct

Shareholder dilution

-1.7 pts

15th pct

Capital efficiency

-4.5 pts

5th pct

Profitability

-5.7 pts

12th pct

Free cash flow

-5.7 pts

12th pct

Scale

-6.6 pts

6th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NRXS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Neuraxis, INC (NRXS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NRXS at 32.1/100 on a 32-signal composite quality model, placing it at rank #2,435 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Neuraxis, INC reports quarterly revenue of $1.9M, net income of $-2.1M. Top institutional holders of NRXS by reported 13-F value include AIGH Capital Management, Rosalind Advisors, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NRXS trades on the NYSE exchange and files with the SEC under CIK 1933567. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRXS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neuraxis, INC directly from SEC EDGAR. Neuraxis, INC's 13F Pro composite quality score has ranged between 30 and 32 since 2026, currently 32.1 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$1.9M

Net Income

Q2 2026

$-2.1M

D/E Ratio

Q2 2026

0.01

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+32.9% YoY

$3.6MFY 2025

FY22 $2.7MFY23 $2.5MFY24 $2.7MFY25 $3.6M

Net Income

+5.4% YoY

$-7.8MFY 2025

FY22 $-4.8MFY23 $-14.6MFY24 $-8.2MFY25 $-7.8M

Operating Income

-9.4% YoY

$-7.8MFY 2025

FY22 $-3.4MFY23 $-6.7MFY24 $-7.2MFY25 $-7.8M

EPS (Diluted)

+22.1% YoY

$-0.95FY 2025

FY22 $-2.77FY23 $-4.50FY24 $-1.22FY25 $-0.95

Total Assets

+34.6% YoY

$6.4MFY 2025

FY22 $1.5MFY23 $509.5KFY24 $4.8MFY25 $6.4M

Total Debt

-3.8% YoY

$148.3KFY 2025

FY22 $228.3KFY23 $148.1KFY24 $154.2KFY25 $148.3K

Op. Cash Flow

-5.5% YoY

$-6.4MFY 2025

FY22 $-2.3MFY23 $-6.7MFY24 $-6.1MFY25 $-6.4M

Free Cash Flow

-5.5% YoY

$-6.5MFY 2025

FY22 $-2.3MFY23 $-6.7MFY24 $-6.1MFY25 $-6.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$3.6M +32.9%	$2.7M +9.2%	$2.5M -8.4%	$2.7M	—
Net Income	$-7.8M +5.4%	$-8.2M +43.7%	$-14.6M -206.0%	$-4.8M	—
Operating Income	$-7.8M -9.4%	$-7.2M -7.4%	$-6.7M -97.6%	$-3.4M	—
EPS (Diluted)	$-0.95 +22.1%	$-1.22 +72.9%	$-4.50 -62.5%	$-2.77	—
Total Assets	$6.4M +34.6%	$4.8M +833.8%	$509.5K -65.6%	$1.5M	—
Total Debt	$148.3K -3.8%	$154.2K +4.1%	$148.1K -35.2%	$228.3K	—
Operating Cash Flow	$-6.4M -5.5%	$-6.1M +8.9%	$-6.7M -191.3%	$-2.3M	—
Free Cash Flow	$-6.5M -5.5%	$-6.1M +8.9%	$-6.7M -192.5%	$-2.3M	—

Get alerted when NRXS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Neuraxis, INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NRXS

AIGH Capital Management LLC
$3.8M519,938 sh
Rosalind Advisors, Inc.
$3.0M508,055 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.5M335,793 sh
MONEY CONCEPTS CAPITAL CORP
$1.7M228,029 sh
RENAISSANCE TECHNOLOGIES LLC
$1.2M169,400 sh
MARSHALL WACE, LLP
$941.2K128,755 sh
PARSONS CAPITAL MANAGEMENT INC/RI
$861.2K117,808 sh
Panoramic Capital, LLC
$840.6K115,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$704.7K96,361 sh
CITADEL ADVISORS LLC
$621.7K85,053 sh

Fund	Value	Shares
AIGH Capital Management LLC	$3.8M	519,938
Rosalind Advisors, Inc.	$3.0M	508,055
VANGUARD CAPITAL MANAGEMENT LLC	$2.5M	335,793
MONEY CONCEPTS CAPITAL CORP	$1.7M	228,029
RENAISSANCE TECHNOLOGIES LLC	$1.2M	169,400
MARSHALL WACE, LLP	$941.2K	128,755
PARSONS CAPITAL MANAGEMENT INC/RI	$861.2K	117,808
Panoramic Capital, LLC	$840.6K	115,000
GEODE CAPITAL MANAGEMENT, LLC	$704.7K	96,361
CITADEL ADVISORS LLC	$621.7K	85,053

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NRXS on your watchlist

Track score changes the day Neuraxis, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NRXS a good stock to buy?

13F Pro's AI-powered analysis of Neuraxis, INC (NRXS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NRXS are available on the NRXS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NRXS is classified as a small company.

Which hedge funds own NRXS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NRXS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neuraxis, INC's investment landscape.